All News

Fezolinetant, a nonhormonal selective neurokinin-3 receptor antagonist, significantly reduced frequency and severity of menopause-related VMS in a pivotal phase 3 trial.

Kevin Carneiro, DO, a sports medicine specialist and medical director of the UNC Center for the Study of Retired Athletes, details the broad scope of the specialty and his practice.

Shorter office visit length increased risk for inappropriate antibiotic prescribing, coprescribing of opioids and benzodiazepines, and potentially harmful prescriptions for seniors.

Your daily dose of clinical news you may have missed.

Ketogenic diet comes with cautions, new benefits of bempedoic acid, how to increase GDMT for type 2 diabetes, and CV consequences of cannabis lead findings from ACC 2023.

Your daily dose of clinical news you may have missed.

Youth at the upper range of normal weight had a 26% higher risk of developing hypertension than those in the lower range of normal weight, according to a new study.

Black women who reported perceived interpersonal racism in employment, housing, and interactions with police had a nearly 30% higher risk of CHD than those reporting none.

Beginning on Sept 24, 2024, all women must be notified of their breast density status in mammography reports and encouraged to pursue supplemental screening.

Your daily dose of clinical news you may have missed.

Screening rates for e-cigarette use in primary care were almost two-thirds lower than those for combustible tobacco, alcohol, and illicit substances, according to new data.

Research on myocarditis has found the risk for the condition significantly higher from infection with SARS-CoV-2 vs from mRNA vaccination against it. True or False?

For vaccine-hesitant patients concerned about myocarditis, it may be helpful to provide real-world context. The quiz contains tips on how to do that.

Standing at the kitchen sink, the patient experienced vertigo and near syncope. His vital signs are normal save a discrepancy in SBP between arms. What's your diagnosis?

Zavegepant, the first FDA-approved intranasal CGRP receptor antagonist, could be available in pharmacies by July 2023.

Each of the quotes is taken from a study reviewed on Patient Care during the week and was chosen for the research team’s passion about the clinical implications of their findings.

Delivered intranasally, the fully human anti-CD3 mAb Foralumab modulated T-cell inflammation in COVID-19 and may have wider application, say study authors.

The University of Washington in Seattle opened one of the country's first long COVID clinics, staffed by specialists in rehabilitation and primary care.